Acadia Pharmaceuticals, Inc. (ACAD) Reports In-Line Q3 EPS Loss of $0.10
Tweet
Share
E-mailGet Alerts ACAD Hot Sheet
Price: $23.64 +4.60%
EPS Growth %: -62.5%
Financial Fact:
Net loss: -71.61M
Today's EPS Names:
DTGI, CRMT, MAYS, More
EPS Growth %: -62.5%
Financial Fact:
Net loss: -71.61M
Today's EPS Names:
DTGI, CRMT, MAYS, More
Join SI Premium – FREE
Acadia Pharmaceuticals, Inc. (NASDAQ: ACAD) reported Q3 EPS of ($0.10), in-line with the analyst estimate of ($0.10). Revenue for the quarter came in at $584 thousand versus the consensus estimate of $500 thousand.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Cerebras Systems (CBRS) Misses Q1 EPS, Revenues Beat
- Crown Crafts (CRWS) Reports Q4 EPS of $0.03
- Cerebras Q1 EPS miss sends shares down 9% after-hours
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
